The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' ...

M42 will integrate SOPHiA GENETICS’ MSK-ACCESS® powered with SOPHiA DDM™ technology into its testing infrastructure ...

AstraZeneca (AZ) has announced that a wider range of chronic kidney disease (CKD) patients across England and Wales will be ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...

Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as an option to treat chronic ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians recommending that many patients with diabetes take ...

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians ...